Advertisement

Advertisement

Op-Ed

Advertisement

Advertisement



Jun
18
Today In Oncology
Serum MicroRNAs for the Diagnosis of Pancreatic and Biliary Tract Cancers
TONIC: PD-1 Blockade in Metastatic Triple-Negative Breast Cancer
U.S. Cancer Survivors Numbered Nearly 17 Million at the Start of 2019
KEYNOTE-001: 5-Year Overall Survival With Pembrolizumab in Advanced NSCLC
Toxicity With Prostate-Only vs Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy
View More 
;
Advertisement
Most Read Stories
FDA Approves Polatuzumab Vedotin-piiq in Combination With Bendamustine and a Rituximab Product for DLBCL
2019 ASCO: TOPARP-B Finds Olaparib Shows Efficacy in Men With BRCA-Mutant Prostate Cancer
2019 ASCO: Long-Term Survival With Dabrafenib Plus Trametinib in Metastatic BRAF-Mutated Melanoma
2019 ASCO: Final Analysis of KEYNOTE-048: First-Line Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
FDA Approves Pembrolizumab for the First-Line Treatment of Head and Neck Squamous Cell Carcinoma
View More 
Most Viewed Videos
Hani M. Babiker, MD, on Tumor Treating Fields: A Different Approach to Therapy
Yeon Hee Park, MD, on Metastatic Breast Cancer: Palbociclib, Exemestane, and GnRH Agonist
Kim N. Chi, MD, on Castration-Resistant Prostate Cancer: Cabazitaxel vs Abiraterone or Enzalutamide in the Metastatic Setting
Richard T. Penson, MD, and Don S. Dizon, MD, on Ovarian Cancer: SOLO3 Trial on Olaparib vs Chemotherapy in Relapsed Disease
Suresh S. Ramalingam, MD, on Non–Small Cell Lung Cancer: Pemetrexed, Bevacizumab, or Both as Maintenance Therapy
View More 
© 2019 HSP News Service, L.L.C.